C-PPW7Neuraly
glial activation inhibition, GLP-1R agonism, neuroinflammation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PPW7
C-PPW7C-PPW7glial activation inhibition, GLP-1R agonism, neuroinflammation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Neuraly glial activation inhibition, GLP-1R agonism, neuroinflammation
Neuraly is a clinical-stage biotechnology company developing drugs for progressive neurodegenerative diseases including Parkinson's disease and Alzheimer's disease. Its clinical development strategy focuses on inhibiting pathological glial activation to prevent neuronal cell death. NLY01 is described as a proprietary long-acting analogue of exendin-4 and GLP-1 receptor agonist being developed as a disease-modifying agent.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Neuraly — Translational · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic